Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.22
TEVA's Cash to Debt is ranked higher than
52% of the 921 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. TEVA: 0.22 )
TEVA' s 10-Year Cash to Debt Range
Min: 0.08   Max: 1.03
Current: 0.22

0.08
1.03
Equity to Asset 0.50
TEVA's Equity to Asset is ranked higher than
61% of the 842 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. TEVA: 0.50 )
TEVA' s 10-Year Equity to Asset Range
Min: 0.4   Max: 0.59
Current: 0.5

0.4
0.59
Interest Coverage 13.17
TEVA's Interest Coverage is ranked higher than
58% of the 537 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 176.76 vs. TEVA: 13.17 )
TEVA' s 10-Year Interest Coverage Range
Min: 3.6   Max: 328.25
Current: 13.17

3.6
328.25
F-Score: 8
Z-Score: 2.56
M-Score: -2.70
WACC vs ROIC
5.53%
10.00%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 19.49
TEVA's Operating margin (%) is ranked higher than
90% of the 870 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.37 vs. TEVA: 19.49 )
TEVA' s 10-Year Operating margin (%) Range
Min: 8.12   Max: 26.78
Current: 19.49

8.12
26.78
Net-margin (%) 15.07
TEVA's Net-margin (%) is ranked higher than
89% of the 870 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.90 vs. TEVA: 15.07 )
TEVA' s 10-Year Net-margin (%) Range
Min: 5.73   Max: 21.09
Current: 15.07

5.73
21.09
ROE (%) 13.17
TEVA's ROE (%) is ranked higher than
86% of the 894 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.44 vs. TEVA: 13.17 )
TEVA' s 10-Year ROE (%) Range
Min: 4.23   Max: 27
Current: 13.17

4.23
27
ROA (%) 6.52
TEVA's ROA (%) is ranked higher than
83% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.27 vs. TEVA: 6.52 )
TEVA' s 10-Year ROA (%) Range
Min: 2.26   Max: 13.11
Current: 6.52

2.26
13.11
ROC (Joel Greenblatt) (%) 43.55
TEVA's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.08 vs. TEVA: 43.55 )
TEVA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 12.89   Max: 49.79
Current: 43.55

12.89
49.79
Revenue Growth (3Y)(%) 4.80
TEVA's Revenue Growth (3Y)(%) is ranked higher than
71% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.30 vs. TEVA: 4.80 )
TEVA' s 10-Year Revenue Growth (3Y)(%) Range
Min: 4.8   Max: 23.4
Current: 4.8

4.8
23.4
EBITDA Growth (3Y)(%) 10.00
TEVA's EBITDA Growth (3Y)(%) is ranked higher than
79% of the 679 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. TEVA: 10.00 )
TEVA' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -10.4   Max: 47.2
Current: 10

-10.4
47.2
EPS Growth (3Y)(%) 4.80
TEVA's EPS Growth (3Y)(%) is ranked higher than
74% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. TEVA: 4.80 )
TEVA' s 10-Year EPS Growth (3Y)(%) Range
Min: -25.6   Max: 69.8
Current: 4.8

-25.6
69.8
» TEVA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

TEVA Guru Trades in Q1 2014

Paul Tudor Jones 300,000 sh (New)
Jana Partners 2,033,131 sh (New)
Ken Heebner 95,000 sh (New)
Jeremy Grantham 13,400 sh (New)
John Keeley 47,435 sh (New)
Steven Cohen 2,111,200 sh (+16777.40%)
David Dreman 183,323 sh (+24.43%)
Bernard Horn 65,600 sh (+24.24%)
Murray Stahl 16,553 sh (+19.07%)
George Soros 10,310,041 sh (+10.67%)
James Barrow 13,335,767 sh (+9.82%)
NWQ Managers 6,294,655 sh (+5.04%)
Jean-Marie Eveillard 200 sh (unchged)
Stanley Druckenmiller 1,241,000 sh (unchged)
Manning & Napier Advisors, Inc 231,252 sh (-0.10%)
Ronald Muhlenkamp 175,440 sh (-0.51%)
Tom Gayner 694,000 sh (-0.84%)
Michael Price 388,400 sh (-2.90%)
Vanguard Health Care Fund 12,350,900 sh (-6.05%)
Richard Snow 1,708,890 sh (-13.55%)
Diamond Hill Capital 250,886 sh (-28.04%)
Alan Fournier 50,000 sh (-61.54%)
Pioneer Investments 17,818 sh (-77.28%)
Caxton Associates 5,900 sh (-86.25%)
» More
Q2 2014

TEVA Guru Trades in Q2 2014

Jim Simons 504,663 sh (New)
Pioneer Investments 227,765 sh (+1178.29%)
Michael Price 500,000 sh (+28.73%)
Caxton Associates 7,200 sh (+22.03%)
Manning & Napier Advisors, Inc 264,965 sh (+14.58%)
Richard Snow 1,826,799 sh (+6.90%)
Ronald Muhlenkamp 176,855 sh (+0.81%)
Stanley Druckenmiller 1,241,000 sh (unchged)
Tom Gayner 694,000 sh (unchged)
Steven Cohen 1,020,700 sh (unchged)
John Keeley 47,435 sh (unchged)
Bernard Horn 65,600 sh (unchged)
Jean-Marie Eveillard 200 sh (unchged)
Jana Partners Sold Out
Ken Heebner Sold Out
Paul Tudor Jones Sold Out
Alan Fournier Sold Out
Murray Stahl 15,782 sh (-4.66%)
Diamond Hill Capital 231,779 sh (-7.62%)
David Dreman 159,090 sh (-13.22%)
Jeremy Grantham 11,400 sh (-14.93%)
James Barrow 10,868,770 sh (-18.50%)
NWQ Managers 5,085,717 sh (-19.21%)
George Soros 7,273,240 sh (-29.45%)
Vanguard Health Care Fund 7,344,400 sh (-40.54%)
» More
Q3 2014

TEVA Guru Trades in Q3 2014

Jean-Marie Eveillard 1,420,580 sh (+710190.00%)
Manning & Napier Advisors, Inc 293,174 sh (+10.65%)
Diamond Hill Capital 246,377 sh (+6.30%)
John Keeley 47,710 sh (+0.58%)
Ronald Muhlenkamp 176,855 sh (unchged)
Bernard Horn 65,600 sh (unchged)
Pioneer Investments 237,961 sh (unchged)
Michael Price 500,000 sh (unchged)
Jeremy Grantham Sold Out
Caxton Associates Sold Out
Stanley Druckenmiller Sold Out
Murray Stahl Sold Out
David Dreman 157,449 sh (-1.03%)
Richard Snow 1,796,499 sh (-1.66%)
James Barrow 10,370,353 sh (-4.59%)
NWQ Managers 4,698,117 sh (-7.62%)
George Soros 6,231,722 sh (-14.32%)
Vanguard Health Care Fund 5,362,100 sh (-26.99%)
Tom Gayner 444,000 sh (-36.02%)
Jim Simons 264,863 sh (-47.52%)
Steven Cohen 59,200 sh (-94.20%)
» More
Q4 2014

TEVA Guru Trades in Q4 2014

Charles Brandes 3,600 sh (New)
Louis Moore Bacon 180,000 sh (New)
Caxton Associates 19,500 sh (New)
Pioneer Investments 1,035,721 sh (+335.25%)
Steven Cohen 238,000 sh (+302.03%)
Jim Simons 964,663 sh (+264.21%)
Jean-Marie Eveillard 2,448,310 sh (+72.35%)
James Barrow 10,823,115 sh (+4.37%)
Richard Snow 1,856,728 sh (+3.35%)
Bernard Horn 65,600 sh (unchged)
Tom Gayner Sold Out
Manning & Napier Advisors, Inc 293,088 sh (-0.03%)
Ronald Muhlenkamp 176,385 sh (-0.27%)
Diamond Hill Capital 235,205 sh (-4.53%)
Vanguard Health Care Fund 4,923,200 sh (-8.19%)
Michael Price 447,500 sh (-10.50%)
NWQ Managers 4,011,187 sh (-14.62%)
John Keeley 37,955 sh (-20.45%)
George Soros 4,859,966 sh (-22.01%)
David Dreman 119,838 sh (-23.89%)
» More
» Details

Insider Trades

Latest Guru Trades with TEVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Teva Pharmaceutical Industries Ltd

Vanguard Health Care Fund Comments on Teva Pharmaceutical Industries Ltd - Mar 27, 2015

We trimmed into strength our position in Teva (TEVA), an Israel-based global biopharmaceutical company specializing in generic formulations. The stock rose substantially on a combination of speculation around M&A in the sector, enthusiasm for the new CEO, and the strong conversion of once-daily Copaxone to the three-times-a-week version.

From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report

Check out Vanguard Health Care Fund latest stock trades

Diamond Hill Capital Comments on Teva Pharmaceutical Industries Ltd - Jun 26, 2014

Generic drug manufacturer Teva Pharmaceutical Industries Ltd. (TEVA) benefitted from the addition of a well-respected CEO and the continued successful transition of patients to a new, patent-protected version of the company’s multiple sclerosis drug.



From Diamond Hill Capital's Select Fund Commentary – First Quarter 2014.



Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Teva Pharmaceutical Industries Ltd

Vanguard Health Care Fund Comments on Teva Pharmaceutical Industries Ltd
We trimmed into strength our position in Teva (TEVA), an Israel-based global biopharmaceutical company specializing in generic formulations. The stock rose substantially on a combination of speculation around M&A in the sector, enthusiasm for the new CEO, and the strong conversion of once-daily Copaxone to the three-times-a-week version. Read more...
The Gurus’ Favorite Asian Stocks
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see which companies based in Asian countries were held by the highest number of gurus. The following five companies come from a variety of industries, are Asian-based and are held by the largest number of gurus. Read more...
Diamond Hill Capital Comments on Teva Pharmaceutical Industries Ltd
Generic drug manufacturer Teva Pharmaceutical Industries Ltd. (TEVA) benefitted from the addition of a well-respected CEO and the continued successful transition of patients to a new, patent-protected version of the company’s multiple sclerosis drug. Read more...
Diamond Hill Select Fund Commentary – First Quarter 2014
The Fund increased 3.08% (Class I) during the quarter, compared to a 1.97% increase in the Russell 3000 Index. Read more...
Top Guru Held Asian Companies of the First Quarter
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see which companies based in Asian countries were held by the highest number of gurus. The following five companies come from a variety of industries, are Asian-based and are held by the largest number of gurus. Read more...
George Soros Reports Top Five Stocks
George Soros (Trades, Portfolio) and his fund Soros Fund Management recently announced their first quarter portfolio holdings which highlighted 151 new buys. The fund now holds on to 305 stocks valued at over $10.1 billion. The following five stocks are his five largest holdings as of the close of the first quarter. Read more...
Richard Snow's Top Five Highlight Finance and Healthcare Sectors
Richard Snow (Trades, Portfolio) of Snow Capital Management released his first quarter holdings earlier today. These holdings highlight 121 stocks valued at $2.55 billion. The guru added 18 new stocks over the quarter for a quarter-over-quarter turnover of 17%. According to the fund’s Investing Philosophy, they look for companies that are financially strong, but with stock prices that have been depressed due to temporary or intermediate-term difficulties. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 17.10
TEVA's P/E(ttm) is ranked higher than
92% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 49.40 vs. TEVA: 17.10 )
TEVA' s 10-Year P/E(ttm) Range
Min: 10.53   Max: 1072.29
Current: 17.1

10.53
1072.29
Forward P/E 12.00
TEVA's Forward P/E is ranked higher than
95% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 67.57 vs. TEVA: 12.00 )
N/A
PE(NRI) 17.40
TEVA's PE(NRI) is ranked higher than
93% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 49.00 vs. TEVA: 17.40 )
TEVA' s 10-Year PE(NRI) Range
Min: 10.53   Max: 938.25
Current: 17.4

10.53
938.25
P/B 2.30
TEVA's P/B is ranked higher than
78% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.76 vs. TEVA: 2.30 )
TEVA' s 10-Year P/B Range
Min: 1.37   Max: 5.05
Current: 2.3

1.37
5.05
P/S 2.62
TEVA's P/S is ranked higher than
75% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.26 vs. TEVA: 2.62 )
TEVA' s 10-Year P/S Range
Min: 1.58   Max: 5.86
Current: 2.62

1.58
5.86
PFCF 15.90
TEVA's PFCF is ranked higher than
94% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 639.25 vs. TEVA: 15.90 )
TEVA' s 10-Year PFCF Range
Min: 8.45   Max: 47.95
Current: 15.9

8.45
47.95
POCF 10.42
TEVA's POCF is ranked higher than
95% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 37.05 vs. TEVA: 10.42 )
TEVA' s 10-Year POCF Range
Min: 6.56   Max: 30.63
Current: 10.42

6.56
30.63
EV-to-EBIT 15.45
TEVA's EV-to-EBIT is ranked higher than
90% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.20 vs. TEVA: 15.45 )
TEVA' s 10-Year EV-to-EBIT Range
Min: 11.7   Max: 991
Current: 15.45

11.7
991
PEG 3.63
TEVA's PEG is ranked higher than
88% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. TEVA: 3.63 )
TEVA' s 10-Year PEG Range
Min: 0.35   Max: 174.07
Current: 3.63

0.35
174.07
Shiller P/E 21.90
TEVA's Shiller P/E is ranked higher than
89% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 111.29 vs. TEVA: 21.90 )
TEVA' s 10-Year Shiller P/E Range
Min: 14.08   Max: 78.77
Current: 21.9

14.08
78.77
Current Ratio 1.17
TEVA's Current Ratio is ranked higher than
54% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. TEVA: 1.17 )
TEVA' s 10-Year Current Ratio Range
Min: 1.06   Max: 2.95
Current: 1.17

1.06
2.95
Quick Ratio 0.82
TEVA's Quick Ratio is ranked higher than
51% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. TEVA: 0.82 )
TEVA' s 10-Year Quick Ratio Range
Min: 0.69   Max: 2.18
Current: 0.82

0.69
2.18
Days Inventory 189.56
TEVA's Days Inventory is ranked higher than
64% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 148.81 vs. TEVA: 189.56 )
TEVA' s 10-Year Days Inventory Range
Min: 131.65   Max: 208.14
Current: 189.56

131.65
208.14
Days Sales Outstanding 97.37
TEVA's Days Sales Outstanding is ranked higher than
69% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 78.61 vs. TEVA: 97.37 )
TEVA' s 10-Year Days Sales Outstanding Range
Min: 95.91   Max: 153.21
Current: 97.37

95.91
153.21

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.20
TEVA's Dividend Yield is ranked higher than
74% of the 529 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.42 vs. TEVA: 2.20 )
TEVA' s 10-Year Dividend Yield Range
Min: 0.2   Max: 3.26
Current: 2.2

0.2
3.26
Dividend Payout 0.38
TEVA's Dividend Payout is ranked higher than
98% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. TEVA: 0.38 )
TEVA' s 10-Year Dividend Payout Range
Min: 0.05   Max: 0.86
Current: 0.38

0.05
0.86
Dividend growth (3y) 15.30
TEVA's Dividend growth (3y) is ranked higher than
87% of the 364 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. TEVA: 15.30 )
TEVA' s 10-Year Dividend growth (3y) Range
Min: -6.7   Max: 80.9
Current: 15.3

-6.7
80.9
Yield on cost (5-Year) 6.24
TEVA's Yield on cost (5-Year) is ranked higher than
96% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.62 vs. TEVA: 6.24 )
TEVA' s 10-Year Yield on cost (5-Year) Range
Min: 0.57   Max: 9.25
Current: 6.24

0.57
9.25
Share Buyback Rate 1.30
TEVA's Share Buyback Rate is ranked higher than
95% of the 658 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -1.60 vs. TEVA: 1.30 )
TEVA' s 10-Year Share Buyback Rate Range
Min: 2.6   Max: -10.9
Current: 1.3

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.00
TEVA's Price/DCF (Projected) is ranked higher than
95% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.40 vs. TEVA: 1.00 )
TEVA' s 10-Year Price/DCF (Projected) Range
Min: 0.6   Max: 7.38
Current: 1

0.6
7.38
Price/Median PS Value 0.80
TEVA's Price/Median PS Value is ranked higher than
93% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. TEVA: 0.80 )
TEVA' s 10-Year Price/Median PS Value Range
Min: 0.49   Max: 1.7
Current: 0.8

0.49
1.7
Earnings Yield (Greenblatt) 6.30
TEVA's Earnings Yield (Greenblatt) is ranked higher than
88% of the 918 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. TEVA: 6.30 )
TEVA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 8.6
Current: 6.3

0.1
8.6
Forward Rate of Return (Yacktman) -1.81
TEVA's Forward Rate of Return (Yacktman) is ranked higher than
66% of the 520 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.39 vs. TEVA: -1.81 )
TEVA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2   Max: 51.2
Current: -1.81

-2
51.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, AGN, FRX, MRX, ESALF » details
Traded in other countries:TEVJF.USA, TEV.Germany, TEVA.Israel, TEVA.Switzerland,
Teva Pharmaceutical Industries Ltd was incorporated in Israel on February 13, 1944. The Company manufactures generic pharmaceutical products. It operates in business in two segments such as generic products, which includes chemical and therapeutic equivalents of originator pharmaceuticals in a variety of dosage forms, including tablets, capsules, ointments, creams, liquids, injectables and inhalants, as well as API business; and specialty products, which includes several core franchises, medicines for CNS disorders (with a strong emphasis on MS, neurodegenerative disorders, and pain) and respiratory medicines, as well as other areas such as oncology and women's health. In addition to these two segments, the Company has other activities, primarily PGT Healthcare, OTC joint venture with P&G, distribution services primarily in Israel and Hungary, and sales of medical devices. The Company, along with its subsidiaries operates in approximately 60 countries. It develops, manufactures and sell generic pharmaceutical products in a variety of dosage forms, including tablets, capsules, ointments, creams, liquids, injectables and inhalants. Specialty medicines business, which is focused on delivering solutions to patients and providers via medicines, devices and services in all key regions and markets around the world, includes several core therapeutic areas, medicines for CNS disorders (with a strong emphasis on MS, neurodegenerative disorders, and pain) and respiratory medicines. Some of its products are Copaxone, Azilect & Provigil, among others. The Company markets approximately 375 generic products in more than 1,100 dosage strengths and packaging sizes, including oral, injectables and inhaled products. The Company is subject to extensive regulation by the United States federal government, principally by the FDA and the Drug Enforcement Administration ("DEA").
» More Articles for TEVA

Headlines

Articles On GuruFocus.com
Vanguard Health Care Fund Comments on Teva Pharmaceutical Industries Ltd Mar 27 2015 
Vanguard Health Care Fund 2014 Annual Report Mar 27 2015 
Impax Laboratories Inc. Steps Into Profitable Zone Feb 26 2015 
Analysts are Bullish on IntelliPharmaceuticals Following Deal with Teva Pharmaceuticals Feb 04 2015 
Weekly 52-Week Highs Highlight: ITW, ESRX, TEVA, CHD, STI Dec 08 2014 
Zoetis in a Growing Global Animal Health Industry Dec 03 2014 
Why Opko Health Is a Better Investment Than Apple Dec 02 2014 
The Gurus’ Favorite Asian Stocks Sep 07 2014 
George Soros Reveals His Largest Stake Jul 23 2014 
George Soros Keeps Buying TEVA, EQT, YPF, EGN, CZR And Keeps Selling GOOGL, BA, MSFT, HAR Jul 16 2014 

More From Other Websites
What Helps a Generic Company Boost Its Profitability? Mar 28 2015
PepsiCo, Inc. (PEP), EMC Corporation (EMC): Hedge Fund Tigershark Partners to Close Doors Mar 26 2015
Teva Announces Pricing of €2 Billion of Senior Notes Mar 24 2015
Teva Announces Pricing of €2 Billion of Senior Notes Mar 24 2015
Citi thinks pharmaceutical giant Teva is set for a 'material, potentially transformative,... Mar 24 2015
Why Teva Pharmaceuticals Could Gain 25% Mar 24 2015
Does Teva Pharmaceutical's New Executive Hint At A Coming M&A Deal? Mar 24 2015
Teva Pharmaceutical Finance Netherlands II BV -- Moody's rates Teva's new Euro notes A3; stable... Mar 24 2015
Teva Migraine Drug Scores In Race With Alder, Lilly Mar 23 2015
Teva Announces New Head of Business Development, Strategy and Innovation Mar 23 2015
Teva Announces New Head of Business Development, Strategy and Innovation Mar 23 2015
Teva’s TEV-48125 Meets Primary and Secondary Endpoints in Episodic Migraine Study, Demonstrating... Mar 23 2015
Teva’s TEV-48125 Meets Primary and Secondary Endpoints in Episodic Migraine Study, Demonstrating... Mar 23 2015
Teva Sells Four Oncology Development Assets to Ignyta - Analyst Blog Mar 18 2015
Uncertainty Abounds In Israel, But Stock Market Thrives Mar 17 2015
Teva and Ignyta Announce Acquisition by Ignyta of Four Oncology R&D Assets from Teva Mar 17 2015
Teva and Ignyta Announce Acquisition by Ignyta of Four Oncology R&D Assets from Teva Mar 17 2015
Teva Pharmaceuticals: Time for a Shopping Spree…and These Companies Could Be Targets Mar 17 2015
Mylan And Teva Are Catching The M&A Fever Mar 16 2015
Three trades to go before the closing bell Mar 16 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK